Eisai Shares Fall Most In 6 Years on Alzheimer’s Drug Data

Eisai Co.’s shares dropped the most in more than six years after partner Biogen Idec Inc.’s experimental Alzheimer’s drug failed to show a statistically significant cognitive benefit for patients on a key dose.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.